Low‑dose anlotinib combined with EGFR‑TKI can be used as an alternative for EGFR‑TKI‑resistant non‑small cell lung cancer in elderly patients-Reference-Cited by-同舟云学术

Low‑dose anlotinib combined with EGFR‑TKI can be used as an alternative for EGFR‑TKI‑resistant non‑small cell lung cancer in elderly patients

Author:

Chen Yi¹,Jiang Nanyuan²,Liang Xiao¹,Chen Nan³,Chen Yun¹,Zhang Chen¹,Shi Junfeng⁴,Guo Renhua¹

Affiliation:

1. Department of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210000, P.R. China

2. Department of Oncology, Nanjing Pukou Central Hospital, Pukou Branch Hospital of Jiangsu Province Hospital, Nanjing, Jiangsu 210000, P.R. China

3. Department of Outpatient, General Hospital of Eastern Theater Command, Nanjing, Jiangsu 210000, P.R. China

4. Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu 210006, P.R. China

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology

Reference47 articles.

1. Cancer statistics, 2020;Siegel;CA Cancer J Clin,2020

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献